NASDAQ:BPTS Biophytis (BPTS) Stock Forecast, Price & News $1.24 -0.06 (-4.62%) (As of 09/29/2023 08:52 PM ET) Add Compare Share Share Today's Range$1.19▼$1.2950-Day Range$0.92▼$2.0652-Week Range$0.88▼$9.02Volume98,600 shsAverage Volume561,130 shsMarket Capitalization$8.48 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Biophytis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,109.7% Upside$15.00 Price TargetShort InterestHealthy0.97% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.09) to ($0.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBiophytis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Biophytis has a forecasted upside of 1,109.7% from its current price of $1.24.Amount of Analyst CoverageBiophytis has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.97% of the outstanding shares of Biophytis have been sold short.Short Interest Ratio / Days to CoverBiophytis has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biophytis has recently decreased by 3.63%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBiophytis does not currently pay a dividend.Dividend GrowthBiophytis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPTS. Previous Next 3.1 News and Social Media Coverage News SentimentBiophytis has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Biophytis this week, compared to 1 article on an average week.Search Interest2 people have searched for BPTS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Biophytis to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biophytis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Biophytis is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biophytis are expected to grow in the coming year, from ($0.09) to ($0.06) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Biophytis (NASDAQ:BPTS) StockBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Read More BPTS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPTS Stock News HeadlinesSeptember 29, 2023 | proactiveinvestors.comBiophytis shares surge 41% following Covid partnership with France's SkyepharmaSeptember 26, 2023 | finance.yahoo.comBiophytis (BPTS) Soars 73% on Partnership With SkyepharmaOctober 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 25, 2023 | benzinga.comWhy Biophytis (BPTS) Shares Are Sky-RocketingSeptember 25, 2023 | markets.businessinsider.comBiophytis Shares Surge 79% Following Covid-19 Partnership With SkyepharmaSeptember 25, 2023 | marketwatch.comBiophytis Shares Rise 41% After Partnership Deal With SkyepharmaSeptember 25, 2023 | finance.yahoo.comBiophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)September 25, 2023 | msn.comWhy Is Biophytis (BPTS) Stock Up 49% Today?October 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 25, 2023 | finance.yahoo.comBiophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)September 20, 2023 | finanznachrichten.deBiophytis Provides an Update on its Early Access Programs for Sarconeos in the Treatment of Severe Forms of COVID-19September 19, 2023 | finance.yahoo.comBiophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19September 14, 2023 | finance.yahoo.comBiophytis Strengthens its Management Team with the Appointment of its Chief Business OfficerSeptember 11, 2023 | finanznachrichten.deBiophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in SarcopeniaSeptember 11, 2023 | finance.yahoo.comBiophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in SarcopeniaSeptember 4, 2023 | finance.yahoo.comBiophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New YorkAugust 16, 2023 | finance.yahoo.comBiophytis Announces Next Regulatory Steps in Europe and the United States for its COVA ProjectAugust 8, 2023 | msn.comWhy Is Biophytis (BPTS) Stock Up 18% Today?August 8, 2023 | finance.yahoo.comBiophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in EuropeJuly 20, 2023 | marketwatch.comBiophytis Shares Drop 11% After Request for Meeting With FDA on Covid-19 TreatmentJuly 20, 2023 | finance.yahoo.comBiophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19July 20, 2023 | finance.yahoo.comBiophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19July 19, 2023 | marketwatch.comBiophytis Shares Drop 12% on Direct Offering PricingJuly 19, 2023 | finanznachrichten.deBiophytis Announces USD3.8 Million Registered Direct OfferingJuly 19, 2023 | finance.yahoo.comBiophytis Announces $3.8 Million Registered Direct OfferingJuly 18, 2023 | seekingalpha.comiCAD, Biophytis top healthcare gainers; Lixte, Masimo lead losers packJuly 18, 2023 | benzinga.comWhy Are Biophytis Shares Skyrocketing Today?See More Headlines Receive BPTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter. Email Address BPTS Company Calendar Today10/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPTS CUSIPN/A CIK1768946 Webwww.biophytis.com Phone33-1-44-37-23-00FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+1,109.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.84) per share Price / Book-1.48Miscellaneous Outstanding Shares5,100,000Free Float4,910,000Market Cap$6.32 million OptionableNot Optionable Beta1.03 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Stanislas Veillet Ph.D. (Age 58)Chairman & CEO Comp: $456.76kMr. Nicolas Fellmann (Age 55)Chief Financial Officer Mr. Waly Dioh Ph.D. (Age 54)Chief Clinical Operating Officer Dr. Pierre J. Dilda (Age 53)Chief Scientific Officer Dr. Rene Lafont (Age 77)Scientific Advisor & Member of Scientific Advisory Board Dr. Rob van Maanen FFPM (Age 53)M.B.A., M.D., Chief Medical Officer Ms. _ TeylanFinancial ControllerMore ExecutivesKey CompetitorsApplied Molecular TransportNASDAQ:AMTIExicureNASDAQ:XCURTenax TherapeuticsNASDAQ:TENXDMK PharmaceuticalsNASDAQ:DMKKintara TherapeuticsNASDAQ:KTRAView All Competitors BPTS Stock - Frequently Asked Questions Should I buy or sell Biophytis stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPTS shares. View BPTS analyst ratings or view top-rated stocks. What is Biophytis' stock price forecast for 2023? 1 brokerages have issued 1 year price objectives for Biophytis' stock. Their BPTS share price forecasts range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,109.7% from the stock's current price. View analysts price targets for BPTS or view top-rated stocks among Wall Street analysts. How have BPTS shares performed in 2023? Biophytis' stock was trading at $3.9510 at the start of the year. Since then, BPTS stock has decreased by 68.6% and is now trading at $1.24. View the best growth stocks for 2023 here. When did Biophytis' stock split? Shares of Biophytis reverse split on Thursday, March 30th 2023. The 1-10 reverse split was announced on Thursday, March 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Biophytis IPO? (BPTS) raised $20 million in an IPO on Wednesday, February 10th 2021. The company issued 1,200,000 shares at $15.00-$18.00 per share. H.C. Wainwright acted as the underwriter for the IPO. What is Biophytis' stock symbol? Biophytis trades on the NASDAQ under the ticker symbol "BPTS." How do I buy shares of Biophytis? Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biophytis' stock price today? One share of BPTS stock can currently be purchased for approximately $1.24. How much money does Biophytis make? Biophytis (NASDAQ:BPTS) has a market capitalization of $6.32 million. How can I contact Biophytis? Biophytis' mailing address is SORBONNE UNIVERSITY BC 9 BATIMENT A 4EME ETAGE 4 PLACE JUSSIEU, PARIS I0, 75252. The official website for the company is www.biophytis.com. The company can be reached via phone at 33-1-44-37-23-00. This page (NASDAQ:BPTS) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.